Hansen Group contributes to GALAXY WP2, Wp4, and WP6.
In the molecular understanding of metabolic diseases, including non-alcoholic and alcoholic fatty liver and liver fibrosis, a major gap exists between basic genetic and microbiome discoveries and their impact on physiology and the potential for clinical translation. The Hansen Group aims to bridge this gap by bringing together genomics discovery and epidemiology, leading to a physiological and clinical understanding of genomics in metabolism.
To study the role of selected genetic variants in human metabolism, they perform physiology and intervention studies based on recruit-by-genotype principles. They also investigate families and populations with extreme metabolic phenotypes and perform physiology and intervention studies in selected individuals with specific microbiome signatures. Finally, they investigate targeted clinical management of carriers of selected high-impact variations in the human genome.
